Name, + highest degree.: Qingfeng He, Pharm.D.
Position title: Assistant Professor
Email: qf_he@fudan.edu.cn
Phone: +86-18721652110
Address: 3728 Jinke Road, Pudong New District, Shanghai, China
Personal website in English if any: NA
Qingfeng He, Pharm.D., serves as an assistant professor in the Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy at Fudan University. Dr. He completed his Pharm.D. at the University of Nebraska Medical Center in May 2020 and subsequently commenced post-doctoral training at Fudan University in September 2020, specializing in clinical pharmacology through quantitative modeling and simulation. In the past three years, Dr. He has published over ten research papers. His work primarily focuses on advancing drug discovery and precision medicine through physiologically-based pharmacokinetic (PBPK) modeling, securing one national research program and three provincial fundings, with multiple translational projects in terms of drug-drug interactions and drug-induced liver injury assessment.
Pharmacotherapy; Clinical Pharmacy; Physiologically-based Pharmacokinetics (PBPK) Modeling; Model-informed drug development; Drug-induced Liver Injury (DILI)
ACADEMIC BACKGROUND
University of Nebraska Medical Center, Doctor of Pharmacy (Graduate with Distinction)
2012.9 - 2016.6
Fudan University, School of Pharmacy, Bachelor of Pharmaceutical Science (Graduate with Distinction)
WORK EXPERIENCE
2022.11 - Present
Fudan University, Department of Clinical Pharmacy and Pharmacy Administration, Assistant Professor
2020.9 - 2022.10
Fudan University, School of Pharmacy, Post-doctoral Research Fellow in Clinical Pharmacology
2019.9 - 2020.5
Nebraska Medicine Outpatient Pharmacy, Pharmacy Intern (Supervisor: Colleen Malashock, Pharm.D., BCPS)
2017.1 - 2020.5
Nebraska Medicine Inpatient Pharmacy, Pharmacy Intern (Supervisor: Allison Beachler, Pharm.D., BCPS)
PUBLICATIONS
1. Qingfeng He; Yang Li; Sifan Liu; Hao Xue; Xiaoqiang Xiang; Tao Wang; Zheng Feng. Drug-induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis. British Journal of Clinical Pharmacology. 2024, 1017:16318.
2. Wen Yao Mak#;Qingfeng He#; Wenyu Yang; Nuo Xu; Aole Zheng; Min Chen; Jiaying Li; Yufei Shi; Xiaoqiang Xiang; Xiao Zhu. Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives. Advanced Drug Delivery Reviews. 2024,214:115447.
3. Qingfeng He#; Min Li#; Peiying Ji; Aole Zheng; Li Yao; Xiao Zhu; Jae-Gook Shin; Volker M Lauschke; Bing Han; Xiaoqiang Xiang. Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach. Toxicology and Applied Pharmacology. 2024,491:117064.
4. Wen Yao Mak#; Qingfeng He#; Wenyu Yang; Nuo Xu; Aole Zheng; Min Chen; Jiaying Lin; Yufei Shi; Xiaoqiang Xiang; Xiao Zhu. Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives. Advanced Drug Delivery Reviews. 2024,214:115447.
5. Haini Wen#; Qingfeng He#; Xiaoqiang Xiang; Zheng Jiao; Jianguang Yu. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thrombosis Research. 2022,218:24-34.
6. Qingfeng He#; Fengjiao Bu#; Qizhen Wang; Min Li; Jiaying Lin; Zhijia Tang; Wen Yao Mak; Xiaomei Zhuang; Xiao Zhu; Hai-shu Lin; Xiaoqiang Xiang. Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. International Journal of Molecular Sciences. 2022,23(9):4485.
7. Zhipin Jin#; Qingfeng He#; Xiao Zhu; Mingshe Zhu; Yike Wang; Xin-an Wu; Qianzhou Lv; Xiaoqiang Xiang. Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes. Basic & Clinical Pharmacology & Toxicology. 2022,130(5):592-605.
8. Qingfeng He#; Fengjiao Bu#; Hongyan Zhang; Qizhen Wang; Xiaoqiang Xiang. Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Pharmaceuticals. 2021,14(3):198.
9. Min Li#;Qingfeng He#; Li Yao; Xiaofeng Wang; Zhijia Tang; Xiao Zhu; Hai-Shu Lin; Xiaoqiang Xiang. Simultaneous Quantification of Propylthiouracil and Its N-β-d Glucuronide by HPLC-MS/MS: Application to a Metabolic Study. Pharmaceuticals. 2021,14(11):1194.
10. Jiayin Lin; Min Li; Wenyao Mak; Yufei Shi; Xiao Zhu; Zhijia Tang; Qingfeng He*; Xiaoqiang Xiang*. Applications of In Silico Models to Predict Drug-Induced Liver Injury.Toxics. 2022,10(12):788.
11. Qiuyu Jia#; Qingfeng He#; Li Yao; Min Li; Jiaying Lin; Zhijia Tang; Xiao Zhu; Xiaoqiang Xiang. Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview. Molecules. 2022,27(24):8670.
12. Nuo Xu; Yufei Shi; Yixue Wang; Wenyao Mak; Wenyu Yang; Kar Weng Ng; Yue Wu; Zhijia Tang; Qingfeng He; Gangfeng Yan; Xiaoqiang Xiang; Xiao Zhu. Development and Quality Control of a Population Pharmacokinetic Model Library for Caspofungin. Pharmaceutics. 2024, 16(6):819.
13. Jiaying Lin; Fengjiao Bu; Dan Wu; Pin Jiang;Qingfeng He; Dongsheng Yang; Xiao Zhu; Yixue Wang; Xiaoqiang Xiang. Physiologically Based Pharmacokinetic Modeling and Clinical Extrapolation for Topical Application of Pilocarpine on Eyelids: A Comprehensive Study. Journal of Pharmaceutical Sciences. 2024
14. Xin Liu; Gehang Ju; Wenyu Yang; Lulu Chen; Nuo Xu; Qingfeng He; Xiao Zhu; Dongsheng Ouyang. Escitalopram personalized dosing: a population pharmacokinetics repository method. Drug Design, Development and Therapy. 2024: 2955-2967.
15. Xin Liu; Gehang Ju; Xinyi Huang; Wenyu Yang; Lulu Chen; Chao Li; Qingfeng He; Nuo Xu; Xiao Zhu; Dongsheng Ouyang. Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype. Journal of Affective Disorders. 2024(346): 64-74.
16. Xiaowen Wang; Yiqun Yu; Hongrui Liu; Fengjiao Bu; Chunying Shen;Qingfeng He; Xiao Zhu; Pin Jiang; Bing Han; Xiaoqiang Xiang. Prediction of Drug–Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model. Drug Metabolism and Disposition. 2023, 51(11):1515-1526.
17. Aole Zheng; Dongsheng Yang; Chunyang Pan; Qingfeng He; Xiaoqiang Xiang; Peiyang Ji. Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A. European Journal of Pharmaceutical Sciences. 2024, 196: 106757.
18. Gehang Ju; Xin Liu; Wenyu Yang; Nuo Xu; Lulu Chen; Chenchen Zhang; Qingfeng He; Xiao Zhu; Dongsheng Ouyang. Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository. Drug Design, Development and Therapy. 2024: 801-818.
19. Yali Wu; Lili Chen; Jian Chen; Hao Xue; Qingfeng He; Dafang Zhong; Xingxing Diao. Covalent binding mechanism of Furmonertinib and Osimertinib with human serum albumin. Drug Metabolism and Disposition. 2023,51(1)8-16.
20. Xiwei Ji, Xiangrui Meng, Qingfeng He, Xiaoqiang Xiang, Yufei Shi, Xiao Zhu. Foretinib is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 in vitro and in vivo by Down-Regulating p-MET/HGF Signaling. International Journal of Molecular Sciences. 2023,24(1):757.
CERTIFICATES
2024.12 U.S. Food & Drug Administration, CDER Small Business and Industry Assistance
FDA Clinical Investigator Training Course
2024.6 esqLabs Workshop at PAGE
PBBM - Formulation development and virtual Bioequivalence
2024.3 University of Tennessee Health Center (Bernd Meibohm) and Metrum (Stacey Tannenbaum)
2nd Asian Pacific Training Course on Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins
2023.6 esqLabs Workshop at PAGE
Physiologically-based Pharmacokinetics (PBPK) & Quantitative Systems Pharmacology (QSP) Modeling
2022.6 National Institutes of Health, Office of Clinical Research
Principles of Clinical Pharmacology Workshop
2022.4 Certara UK, Simcyp Division
Intensive 2-day Workshop on Model-informed Drug Development
PROFESSIONAL INVOLVEMENT
ACCP (American College of Clinical Pharmacology, since 2022)
ISoP (International Society of Pharmacometrics, since 2022)
ISSX (International Society for the Study of Xenobiotics, since 2021)
